HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $13.97, but opened at $13.42. HUTCHMED shares last traded at $13.26, with a volume of 42,252 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Read Our Latest Analysis on HCM
HUTCHMED Stock Performance
The business's fifty day moving average price is $14.78 and its two-hundred day moving average price is $17.17. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Institutional Trading of HUTCHMED
A number of large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new position in HUTCHMED during the 2nd quarter valued at about $213,000. Blue Trust Inc. grew its holdings in HUTCHMED by 638.2% during the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock valued at $117,000 after purchasing an additional 2,321 shares during the last quarter. M&G PLC grew its holdings in HUTCHMED by 98.1% during the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Finally, Crossmark Global Holdings Inc. bought a new position in HUTCHMED during the 3rd quarter valued at about $328,000. 8.82% of the stock is currently owned by institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
